Table 4.

Characteristics of patients who developed cardiac toxicities during the follow-up period

	Grade 1								Grade 2
	1	2	3	4	5	6	7	8	1	2
Age, years
17–40
41–50			x		x
51–60					x				x
61–65	x	x				x	x		x	x
Performance status
0
1	x			x		x		x
2		x	x		x		x		X	x
Cancer type
Ovarian	x				x		x	x	x
Breast		x		x						x
Endometrial				x			x
Paclitaxel
Single agent
Weekly	x				x		x
Every 3 weeks		x	x	x						x
Combination						x		x	x
Paclitaxel setting
Neoadjuvant/adjuvant		x			x		x	x
Metastatic/recurrent	x		x	x		x			x	x
Prior treatment
Chemotherapy		x			x					x
Chest wall irradiation		x		x						x
Associated comorbidities
Hypertension	x	x		x					x	x
Hypercholesterolemia	x									x
Diabetes mellitus		x			x				x	x
Ischemic heart disease		x